
Diabetes Overload: Making Sense of the Data

Emily Rohling, PharmD,
Belinda Childs, APRN, BC-ADM, CDCES



GREAT PLAINS
DIABETES



ESTD 1976
DANDURAND
DRUGSTORE

Disclosures

- Emily Rholing, PharmD-No disclosures
- Belinda Childs, APRN
 - Abbott Diabetes -, <\$6000 in research support to Great Plains Diabetes (2021-2023)
 - Embecta-advisory board, paid to Great Plains Diabetes
 - PreventionBio-advisory board, paid to Great Plains Diabetes

Learning Objectives


- Define Continuous Glucose Monitoring (CGM) and the use in improving diabetes management
- Compare and contrast FreeStyle Libre 3 and Dexcom 7
- Identify pumps that integrate CGM in hybrid closed loop systems
- Define Time in Range and goals for different individuals, CV, GMI
- Participants with review case studies to identify patterns and potential solutions

You are the Expert

- We are going to ask you to break into groups of 3. Some will be experts, some will be novices. Those of you who do this every day, find someone who may be less sure of reviewing reports.
- The primary purpose of this session is to learn from each other.
- We only have 45 minutes so we will do a brief introduction and then share reports to review, have 2 or 3 groups share their recommendations.

What is Continuous Glucose Monitoring (CGM)?


- Tiny sensor that is inserted under the skin; measures glucose levels in the interstitial fluid
- Records data every 1-5 minutes \approx 288 finger sticks
- Provides alarms for high and low glucose levels



What Are The Options?



Eversense



Guardian 4
from Minimed
Still looking for
picture



<https://consumerguide.diabetes.org/collections/cgm>
2023

	FreeStyle Libre 3	Dexcom G7
Indications	Used in ages 4 and up; Approved for Type 1, Type 2 diabetes, and gestational	Used in ages 2 and up; Approved in Type 1, Type 2 diabetes, and gestational
Size	Smaller than two stacked pennies	60% smaller than G6 and more circular
Wear Time	14 days	10 days
Warm-Up Time	60 minutes	30 minutes
Glucose Reading Frequency	Every minute	Every 5 minutes

	FreeStyle Libre 3	Dexcom G7
Approved Body Locations	Back of the upper arm	Back of the upper arm Buttocks (age 2 to 6 y/o)
Waterproof (Water Resistance)	30 minutes at 3 feet	24 hours at 8 feet
Smartphone Apps Available	Compatible with iOS and Androids *Refer to website for compatibility*	Compatible with iOS and Androids *Refer to website for compatibility*
Healthcare Provider Apps Available	LibreView	Dexcom Clarity
Retail Price	\$154 for a 28-day supply (quantity 2 sensors) \$75 with Relay Health Coupon	\$444 for a 30-day supply (quantity 3 sensors) Coupon can make this \$89

Why Use CGM?

- Provides people with diabetes as well as providers an expanded knowledge and awareness regarding glucose excursions
- Offers an opportunity to explore the impact of:
 - Food
 - Medications
 - Physical activity
 - Stress
- Provides guidance for medication adjustments, meal planning, physical activity and improve glucose management
- Can be useful in prediabetes-lifestyle changes


Even without diabetes

- 36 y/o, healthy, woman wanted to make improvements in her diet. She usually purchases the Green Juice from Whole Foods. She was curious about how her glucose levels responded to the green juice.




Green Juice vs. Fab 4 Smoothie

Which Breakfast Drink is the "Healthiest" Choice?




Green Juice Effects on Your Blood Sugar Balance










The Bigger Picture


- CGM provides graphs, charts, and analyses of a patient's glucose levels
 - Provides a CGM reading every few minutes
 - Plots data on a trend graph
 - Trend arrows to show the rate of direction
 - Can set high and low glucose alerts



Value of the Trend Arrows


	Constant: your glucose is steady (not increasing/decreasing more than 1 mg/dL each minute)
	Slowly rising: Your glucose is rising 1-2 mg/dL each minute
	Rising: Your glucose is rising 2-3 mg/dL each minute
	Rapidly rising: Your glucose is rising more than 3 mg/dL each minute
	Slowly falling: your glucose is falling 1-2 mg/dL each minute
	Falling: your glucose is falling 2-3 mg/dL each minute
	Rapidly falling: your glucose is falling more than 3 mg/dL each minute
no arrow	No rate of change information: the receiver cannot always calculate how fast your glucose is rising or falling

100% Time In Range




Time in Range Recommendations


Type 1[‡] & Type 2 Diabetes



Older/High-Risk: Type 1 & Type 2 Diabetes



Pregnancy: Type 1 Diabetes[†]



Pregnancy: Gestational & Type 2 Diabetes[§]



‡ For age <25 yr., if the A1C goal is 7.5%, then set TIR target to approximately 60%. (See *Clinical Applications of Time in Ranges* section in the text for additional information regarding target goal setting in pediatric management.)

† Percentages of time in ranges are based on limited evidence. More research is needed.

§ Percentages of time in ranges have not been included because there is very limited evidence in this area. More research is needed. Please see *Pregnancy* section in text for more considerations on targets for these groups.

* Includes percentage of values >250 mg/dL (13.9 mmol/L).

** Includes percentage of values <54 mg/dL (3.0 mmol/L).

AGP (Ambulatory Glucose Profile) Report

- Minimum of 14 day report
- Is on standard print outs of CGM and AIP
- Statistical summary of pt information and glucose exposure
- Visual display with 14 day modal day
- Condensed daily view of glucose excursions
- Average displayed
- Coefficient of variation $< 36\%$ (the higher the CV the more variation

AGP Report

Name _____

MRN _____

GLUCOSE STATISTICS AND TARGETS

26 Feb 2019–10 Mar 2019
% Time CGM is Active

13 days
99.9%

Glucose Ranges

Targets [% of Readings (Time/Day)]

Target Range 70–180 mg/dL Greater than 70% (16h 48min)
 Below 70 mg/dL Less than 4% (58min)
 Below 54 mg/dL Less than 1% (14min)
 Above 180 mg/dL Less than 25% (6h)
 Above 250 mg/dL Less than 5% (1h 12min)

Each 5% increase in time in range (70–180 mg/dL) is clinically beneficial.

Average Glucose

173 mg/dL

Glucose Management Indicator (GMI)


7.6%

Glucose Variability

49.5%


Defined as percent coefficient of variation (%CV); target ≤36%

TIME IN RANGES




AMBULATORY GLUCOSE PROFILE (AGP)

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if occurring in a single day.



DAILY GLUCOSE PROFILES



Each daily profile represents a midnight-to-midnight period.

Tadej Battelino et al. Dia Care 2019;42:1593-1603

GMI (Glucose Management Indicator)

- GMI tells you what your approximate A1C level is likely to be, based on the average glucose level from your CGM readings for 14 or more days.
- What might cause a variation between the GMI and A1c?

Case Study 1: T1DM

- **Background:** 4 y/o girl, T1DM, who has a tradition of spending her Friday nights watching movies and eating pizza with her siblings. Her mom noticed when her daughter ate homemade pizza alone, her glucose levels would spike above **300mg/dL** and crash below **75mg/dL**. Her mom was concerned and contacted the Diabetes Care and Education Specialists at Dandurand's Wellness for diabetes and nutrition counseling.

Take a few minutes to review this report

- **Our Study:** After the individual counseling session, we evaluated her glucose levels with our new recommendations. We collected data from her lunch and dinner on a Friday.

The Menu

- Lunch


- 3:00pm: ate a corn dog

- Dinner

- 5:15pm: Received insulin dose
- 5:25pm: Started eating dinner
 - Broccoli
 - Beef stick
 - Pizza



4 y/o T1DM; Lunch and Dinner Effects on Glucose Levels



Red-dotted line: Time in Range

AUTOMATED INSULIN PUMPS

OmniPod 5



Tandem X2 Control IQ



iLet by BetaBionics



Minimed 780G













Tandem Mobi

<https://consumerguide.diabetes.org/collections/pumps>

Tslim x2 with Control IQ



Tandem X2 with Control IQ

180	  Delivers	Delivers an automatic correction bolus if sensor glucose is predicted to be above 180 mg/dL
160	  Increases	Increases basal insulin delivery if sensor glucose is predicted to be above 160 mg/dL
112.5	  Maintains	Maintains active Personal Profile settings
70	  Decreases	Decreases basal insulin delivery if sensor glucose is predicted to be below 112.5 mg/dL
mg/dL	  Stops	Stops basal insulin delivery if sensor glucose is predicted to be below 70 mg/dL

Role of the Health Care Professional

- Identify patients that would benefit from a CGM device
- Help determine which device best suits the individual needs of the patient
- Educate and counsel on proper placement and upkeep of the device
- Help read and interpret the data to adjust insulin regimens, other diabetic medications, and implement lifestyle modifications

References

- Dexcom. *Dexcom Continuous Glucose Monitoring* | DexCom. <https://www.dexcom.com>
- *Continuous Glucose Monitoring (CGM) | FreeStyle Libre (CGM) systems.* <https://www.freestyle.abbott/us-en/home.html>
- Katie Cook, PharmD Candidate, and PharmD Jonathan Ogurchak. “Continuous Glucose Monitoring: An Opportunity to Understand and Individualize Diabetes Management.” *Pharmacy Times*, 15 Nov. 2021, www.pharmacytimes.com/view/continuous-glucose-monitoring-an-opportunity-to-understand-and-individualize-diabetes-management.
- *Dexcom G7 & Libre 3 comparison.* ADCES. [https://www.diabeteseducator.org/danatech/glucose-monitoring/continuous-glucose-monitors-\(cgm\)/cgm-selection-training/dexcom-g7-libre-3-comparison](https://www.diabeteseducator.org/danatech/glucose-monitoring/continuous-glucose-monitors-(cgm)/cgm-selection-training/dexcom-g7-libre-3-comparison)

References

- American Diabetes Association, Diabetes technology: standards of medical care 2023, *Diab Care* 2023, Jan; 46 (Supplement 1):S97-S110 (glycemic targets), S111-127 (technology)
- Bergenstal R, Beck R, Close, et al. Glucose management indicator (gmi): a new term for estimating A1c from continuous glucose monitoring. *Diab Care* 41(11) 2275-2280.
- Ekhlaspour L, Tabatabai I, & Buckingham B. A review of continuous glucose monitoring data in the age of automated insulin delivery. *JSc&Tech* 13 (4): P 645-663.
- Carlson AL, Mullen, DM, Bergenstal RM. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. *Diabetes Technologies* 2017; (Suppl 2): S4-S11.
- Hirsch IB, Veerderse CA. Professional flash continuous glucose monitoring with ambulatory glucose profile reporting to supplement A1C: rationale and practical implementation. *Endo Practice* 2017; 23:1333-1344.
- Messer LH, Berget C, Forlenza GP. A Clinical Guide to Advanced Diabetes Devices and Closed-Loop Systems Using the CARES Paradigm. *Diabetes Technol Ther*. 2019 Aug;21(8):462-469. doi: 10.1089/dia.2019.0105. Epub 2019 May 29. PMID: 31140878; PMCID: PMC6653788.



clinical@danduranddrugs.com



#danduranddrugs



@Danduranddrugs



Sign up for our newsletter "The Wellness Talk" by emailing us today!



GREAT PLAINS DIABETES CENTER

BELINDA "LINDY" CHILDS, APRN-CNS, BC-ADM, CDCES
JENNIFER SEBES, DNP, NP-C

834 N. SOCORA, SUITE 4
WICHITA, KANSAS 67212
PHONE 316-440-2802
FAX 316-440-2809

EMAIL: INFO@GREATPLAINSDIABETES.COM
WWW.GREATPLAINSDIABETES.COM